The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

"Among patients with heart failure with mildly reduced or preserved ejection fraction in the FINEARTS-HF, who were at relatively low risk of adverse kidney events, finerenone did not alter the ...

Finerenone reduced the risk of the primary composite outcome more effectively in patients enrolled within 7 days (RR, 0.74; 95% CI, 0.57-0.95) and between 7 days and 3 months (RR, 0.79; 95% CI, 0. ...